Navigation Links
Daiichi Sankyo Settled Patent Litigation for Evoxac®
Date:8/4/2010

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Daiichi Sankyo, Inc. and its parent company, Daiichi Sankyo Co., Ltd, (collectively, "Daiichi Sankyo") have reached an agreement with Apotex Inc. and Apotex Corp. (collectively, "Apotex") to settle their patent litigation involving Apotex's challenge to Daiichi Sankyo's U.S. Patent Number 5,340,821 (hereinafter referred to as "the '821 patent") covering Evoxac® (cevimeline HCl).  Under the agreement, Apotex has received a license to the '821 patent that will permit Apotex to commercially launch its generic cevimeline HCl product in the fourth quarter of 2012.

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
2. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
3. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
4. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
5. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
8. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
9. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
10. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Robert G. Szewc, M.D., is recognized ... in recognition of his contributions to the Medical field.  ... Nephrologist at the practice of Kidney and Hypertension Specialists, ... and hypertension solutions. He has worked in this position ... experience, as well as expertise in kidneys, hypertension, chronic ...
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... Physician Partners ... Fla. location at 5304 Main Street as an interventional pain management specialist. , ... and extremities. He joins PPOA from private practice In Brooksville, Fla. His orthopedic background ...
(Date:9/25/2017)... ... ... “Renew Refresh Restore Reward”: is a story of struggle and how trouble often happens ... Freeman, cofounded the Free Spirit Bible Church and currently serves as the church’s Director ... us to come over before the baby had to go back to her grandparents. ...
(Date:9/25/2017)... ... September 25, 2017 , ... The trend-spotters, tastemakers, and healthy lifestyle product experts ... based super herb drinks, with the new NEXTY Gold Award at the Natural Products ... the NEXTY Gold, which is reserved for just those companies that hit high marks ...
(Date:9/24/2017)... ... September 25, 2017 , ... Bhowanie Benimadhu’s new book “ Our ... questions of life and seeks answers in both Eastern and Western religious traditions and ... God is in the mind of humankind for the past thousands of years and ...
Breaking Medicine News(10 mins):